Levi & Korsinsky notifies investors that it has commenced an investigation into Praxis Precision Medicines, Inc. (NASDAQ: PRAX) concerning potential violations of the federal securities laws.
Praxis Precision Medicines, Inc. issued a press release on August 4, 2025, announcing its financial results for the second quarter of 2025. In addition to its financial disclosures, the Company reported mid-stage clinical trial results for its anti-seizure medication, vormatrigine. Praxis disclosed that 36 of 61 patients experienced treatment-emergent adverse events, and nearly 25% of study participants discontinued participation. Following this news, Praxis’s stock price fell over 5% on August 4, 2025.
If you suffered a loss on your Praxis Precision Medicines, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





